Clinical Trial Update: A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test [Phase 2]

View source ↗

Summary

Phase II trial evaluating IdeS to desensitize transplant patients with a positive crossmatch; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Failure

Drugs mentioned

• IdeS (Immunoglobulin-degrading enzyme of Streptococcus pyogenes)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: Kidney Failure, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2021-05-20